002737.SZ
葵花药业
SZSE · Healthcare · C 制造业 · CN
CNY 12.86
−1.38%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.5B | 2.3B | 3.4B | 5.7B | 5.1B |
| Cost of Revenue | 1.4B | 1.4B | 1.9B | 2.5B | 2.2B |
| Gross Profit | 1.1B | 884.4M | 1.5B | 3.2B | 2.9B |
| Operating Expenses | |||||
| R&D Expense | 114.3M | 111.1M | 124.1M | 128.6M | 94.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 414.0M | 420.1M | 423.1M | 472.8M | 476.2M |
| Selling & Marketing Expense | 706.0M | 580.1M | 431.0M | 1.4B | 1.3B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.3B | 1.1B | 1.0B | 2.0B | 1.9B |
| Cost and Expenses | 2.7B | 2.6B | 2.9B | 4.5B | 4.1B |
| Operating Income (EBIT) | (183.7M) | (251.2M) | 636.2M | 1.4B | 1.1B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (199.9M) | (271.2M) | 634.5M | 1.4B | 1.1B |
| Income Tax Expense | 40.3M | 25.9M | 131.8M | 189.8M | 171.4M |
| Bottom Line | |||||
| Net Income | (204.7M) | (257.8M) | 492.0M | 1.1B | 867.2M |
| Earnings from Cont. Ops | (240.1M) | (297.1M) | 502.7M | 1.2B | 909.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (204.7M) | (257.8M) | 492.0M | 1.1B | 867.2M |
| Per Share | |||||
| Basic EPS | (CN¥0.36) | (CN¥0.44) | CN¥0.84 | CN¥1.92 | CN¥1.48 |
| Diluted EPS | (CN¥0.36) | (CN¥0.44) | CN¥0.84 | CN¥1.92 | CN¥1.48 |
| Revenue Per Share | CN¥4.30 | CN¥3.96 | CN¥5.77 | CN¥9.78 | CN¥8.69 |
| Shares | |||||
| Basic Shares Outstanding | 580.5M | 586.0M | 585.8M | 582.9M | 586.0M |
| Diluted Shares Outstanding | 580.5M | 586.0M | 585.8M | 582.9M | 586.0M |
| Profitability Metrics | |||||
| EBITDA | — | (78.4M) | 814.7M | 1.5B | 1.3B |
| D&A | — | 172.8M | 178.5M | 176.9M | 264.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026